Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 16/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576269 | 1.00 | TNFRSF1A (1.00) | TNFRSF1ALMNAGAAMAPTATM | |
| SCHEMBL5575669 | 0.88 | TNFRSF1A (1.00) | TNFRSF1AABCG2 | |
| SCHEMBL5575663 | 0.88 | TNFRSF1A (1.00) | TNFRSF1AABCG2 | |
| SCHEMBL5575643 | 0.87 | TNFRSF1A (0.76) | TNFRSF1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5575647 | 0.87 | TNFRSF1A (0.76) | TNFRSF1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5575987 | 0.86 | TNFRSF1A (1.00) | TNFRSF1AABCG2 | |
| SCHEMBL5575991 | 0.86 | TNFRSF1A (1.00) | TNFRSF1AABCG2 | |
| SCHEMBL5576265 | 0.86 | TNFRSF1A (1.00) | TNFRSF1A | |
| SCHEMBL5576270 | 0.86 | TNFRSF1A (1.00) | TNFRSF1A | |
| SCHEMBL7264904 | 0.84 | TNFRSF1A (0.77) | TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | MENG CHARLES Q | 2006-11-16 | — | — | US | claimed |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS PHARMACEUTICALS, INC. | 2003-12-25 | — | — | US | claimed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | claimed |
| US-7247714-B2 | Protection against oxidative stress and inflammation by a cytoprotective response element | ATHEROGENICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | MENG CHARLES Q | 2006-11-16 | — | — | US | disclosed |
| US-7078431-B2 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040023233-A1 | Protection against oxidative stress and inflammation by a cytoprotective response element | CRABTREE ACQUISITION CO, LLC | 2004-02-05 | — | — | US | disclosed |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS PHARMACEUTICALS, INC. | 2003-12-25 | — | — | US | disclosed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | disclosed |
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023233-A1 | Protection against oxidative stress and inflammation by a cytoprotective response element | ATF4, HSF1, DDIT3 | TNFRSF1A 1169/4885LMNA 1978/4885GAA 4345/4885 |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | TNFRSF1A 183/4885LMNA 2238/4885GAA 684/4885 |
| US-20060258735-A1 | 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | TNFRSF1A 183/4885LMNA 2238/4885GAA 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.